|
10 Oct 2025 |
CCL Products
|
Consensus Share Price Target
|
830.85 |
951.78 |
- |
14.55 |
buy
|
|
|
|
|
08 Aug 2025
|
CCL Products
|
Keynote Capitals Ltd
|
830.85
|
1203.00
|
864.35
(-3.88%)
|
44.79 |
Buy
|
|
|
Quarterly Update Q1FY26
|
|
07 Aug 2025
|
CCL Products
|
IDBI Capital
|
830.85
|
849.00
|
862.65
(-3.69%)
|
Target met |
Hold
|
|
|
CCL Products Q1FY26 profitability was below our expectations. Sales grew 37% YoY to Rs10.7bn, driven by 9-10% YoY volume growth and 27-28% YoY increase in realization due to improved coffee blends. Gross margin contracted by 543bps YoY to 32.6%, driven by higher input cost. Consequently, EBITDA margin contracted by 178bps YoY to 15.1%. EBITDA grew 22% YoY to Rs1.6bn, driven by a favorable product mix in B2B and growth in the B2C category. PAT increased by 1% YoY to Rs724mn. CCL maintained its volume and EBITDA growth guidance of 10-20% and 15-20%, respectively. Management expects some price...
|
|
07 Aug 2025
|
CCL Products
|
Axis Direct
|
830.85
|
970.00
|
862.65
(-3.69%)
|
16.75 |
Buy
|
|
|
With a 12% upside from the CMP, we maintain our BUY rating on the stock.
|
|
07 May 2025
|
CCL Products
|
Keynote Capitals Ltd
|
830.85
|
1126.00
|
772.60
(7.54%)
|
35.52 |
Buy
|
|
|
Quarterly Update Q4FY25
|
|
07 May 2025
|
CCL Products
|
Axis Direct
|
830.85
|
800.00
|
772.60
(7.54%)
|
Target met |
Buy
|
|
|
With a 15% upside from the CMP, we maintain our BUY rating on the stock
|
|
06 May 2025
|
CCL Products
|
IDBI Capital
|
830.85
|
738.00
|
772.60
(7.54%)
|
Target met |
Hold
|
|
|
|
|
07 Feb 2025
|
CCL Products
|
IDBI Capital
|
830.85
|
698.00
|
654.35
(26.97%)
|
Target met |
Hold
|
|
|
|
|
07 Feb 2025
|
CCL Products
|
Keynote Capitals Ltd
|
830.85
|
1146.00
|
654.35
(26.97%)
|
37.93 |
Buy
|
|
|
Quarterly Update Q3FY25
|
|
07 Feb 2025
|
CCL Products
|
Axis Direct
|
830.85
|
730.00
|
654.35
(26.97%)
|
Target met |
Buy
|
|
|
With a 13% upside from the CMP, we maintain our BUY rating on the stock.
|
|
28 Jan 2025
|
CCL Products
|
CD Equisearch
|
830.85
|
681.00
|
599.45
(38.60%)
|
Target met |
Accumulate
|
|
|
|
|
11 Nov 2024
|
CCL Products
|
Keynote Capitals Ltd
|
830.85
|
1222.00
|
713.05
(16.52%)
|
47.08 |
Buy
|
|
|
Quarterly Update Q2FY25
|
|
11 Nov 2024
|
CCL Products
|
BP Wealth
|
830.85
|
|
713.05
(16.52%)
|
|
Results Update
|
|
|
|
|
07 Nov 2024
|
CCL Products
|
IDBI Capital
|
830.85
|
734.00
|
691.70
(20.12%)
|
Target met |
Hold
|
|
|
|
|
07 Nov 2024
|
CCL Products
|
Axis Direct
|
830.85
|
820.00
|
701.40
(18.46%)
|
Target met |
Buy
|
|
|
With a 14% upside from the CMP, we maintain our BUY rating on the stock.
|
|
09 Sep 2024
|
CCL Products
|
Keynote Capitals Ltd
|
830.85
|
1221.00
|
747.05
(11.22%)
|
|
Buy
|
|
|
Initiating Coverage Report
|
|
09 Aug 2024
|
CCL Products
|
Axis Direct
|
830.85
|
760.00
|
659.85
(25.91%)
|
Target met |
Buy
|
|
|
With a 15% upside from the CMP, we maintain our BUY rating on the stock.
|
|
14 May 2024
|
CCL Products
|
Axis Direct
|
830.85
|
670.00
|
563.40
(47.47%)
|
Target met |
Buy
|
|
|
With a 17% upside from the CMP, we maintain our BUY rating on the stock.
|
|
14 May 2024
|
CCL Products
|
IDBI Capital
|
830.85
|
582.00
|
563.40
(47.47%)
|
Target met |
Hold
|
|
|
|
|
30 Mar 2024
|
CCL Products
|
CD Equisearch
|
830.85
|
645.00
|
586.30
(41.71%)
|
Target met |
Hold
|
|
|
|
|
07 Feb 2024
|
CCL Products
|
Axis Direct
|
830.85
|
720.00
|
667.35
(24.50%)
|
Target met |
Buy
|
|
|
With a 12% upside from the CMP, we maintain our BUY rating on the stock.
|